There are few medications in the field of transplantation that evoke such strong opinions as Sirolimus – it is either loved or loathed. Initial concerns about side effects and the 2002 black box warning from the Food and Drug Administration (FDA) regarding the risk of hepatic artery thrombosis (HAT) meant that for many years, Sirolimus was not used widely in liver transplantation. However, recent data show that Sirolimus offers potential benefit in specific areas such as hepatocellular carcinoma (HCC) and hepatitis C virus (HCV)-infected grafts, with acceptable risk to benefit ratios.
No takes yet. Share an insight, caveat, or question.
McKenna et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: